Akums Drugs and Pharmaceuticals Limited — Updates, 26-05-2025: Press Release

Akums has announced a board meeting to approve the financial results for the quarter and half-year. Q4 FY25 revenue rose 12.4% YoY to ₹1,073 Cr, with a 10.4% EBITDA margin. FY25 revenue hit ₹4,170 Cr, maintaining a 12.3% adjusted EBITDA margin. The company secured a €200 million contract to supply pharma products to European regulated markets from 2027, boosting its global CDMO growth. Capex was ₹272 Cr, and R&D spend ₹130 Cr (over 3% of revenue). Domestic and international branded formulations grew 9% and 14%, while trade generics and API remain loss-making but are under turnaround plans.